IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

Application of: Standring, et al.

For: Flaviviridae Mutation Caused by 2-

Branched Nucleosides

POWER OF ATTORNEY BY ASSIGNEE AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71 WITH STATEMENT UNDER 37 C.F.R. 3.73(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

The undersigned assignee of U.S. Provisional Patent Application No. 60/426.675 and U.S. Patent Application No. 10/715.729 hereby appoints Practitioners of Jones Day associated with Customer Number 20583, which mailing address is Jones Day, 222 East 41st Street, New York, New York 10017, as its attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71.

Please direct all correspondence for this application to Customer no. 20583.

Statement Under 37 C.F.R. 3.73(b)

Idenix Pharmaceuticals, Inc. states that it is:

the assignee of the entire right, title, and interest; or
an assignee of less than the entire right, title and interest.

in the patent application/patent identified above by virtue of:

An Assignment from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

From: David Standring, Jean-Pierre Sommadossi, Vadim Bichko, and Lin Qu TO: Idenix Pharmaceuticals, Inc. The document was recorded in the United States Patent and Trademark Office on 09/02/2003 at Reel 014450, Frame 0821.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: Idenix Pharmaceuticals, Inc.

Signature:

Typed Name: Jean-Pierre Orfinnadossi

Position/Title: President and Chief Executive Officer